Table 4.

Adjusted associations of the presence of tumor cell or diffuse tumor vasculature B7-H3 expression with death from RCC for 743 ccRCC patients

FeatureRisk ratio (95% CI)*P
Age at surgery3.08 (2.36-4.03)<0.001
Gender3.10 (2.37-4.05)<0.001
Symptoms at presentation2.84 (2.17-3.72)<0.001
Constitutional symptoms at presentation2.73 (2.07-3.60)<0.001
ECOG performance status3.08 (2.36-4.03)<0.001
Tumor thrombus2.68 (2.04-3.53)<0.001
Primary tumor size2.32 (1.77-3.04)<0.001
2002 Primary tumor classification2.17 (1.65-2.85)<0.001
Regional lymph node involvement3.01 (2.30-3.93)<0.001
Distant metastases2.72 (2.07-3.56)<0.001
2002 TNM stage groupings2.25 (1.71-2.96)<0.001
Nuclear grade1.78 (1.34-2.36)0.003
Coagulative tumor necrosis1.75 (1.31-2.34)<0.001
Sarcomatoid Differentiation2.74 (2.08-3.60)<0.001
TNM stage groupings, nuclear grade, ECOG1.68 (1.27-2.24)<0.001
SSIGN score1.38 (1.03-1.84)0.029
  • * Risk ratio represents the association of the presence of positive tumor cell or diffuse tumor vasculature B7-H3 expression with death from RCC (using negative tumor cell and absent, focal, or moderate tumor vasculature B7-H3 expression as the reference group) after adjustment for the feature or combination of features listed.